|
|
|
|
| LEADER |
01652nam a2200301 u 4500 |
| 001 |
EB001872158 |
| 003 |
EBX01000000000000001035529 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Dapagliflozin (Forxiga)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Dapagliflozin (Forxiga)
|
| 246 |
3 |
1 |
|a CDR pharmacoeconomic review report for Forxiga
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, April 2016
|
| 300 |
|
|
|a 1 PDF file (various pagings)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Hypoglycemic Agents / therapeutic use
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Hypoglycemic Agents / economics
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK538769
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metformin and a sulfonylurea for patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea and for whom insulin is not an option
|